These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 16954464)

  • 41. Summaries for patients. Using breast density to predict breast cancer risk.
    Ann Intern Med; 2008 Mar; 148(5):I34. PubMed ID: 18316748
    [No Abstract]   [Full Text] [Related]  

  • 42. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.
    LaCroix AZ; Powles T; Osborne CK; Wolter K; Thompson JR; Thompson DD; Allred DC; Armstrong R; Cummings SR; Eastell R; Ensrud KE; Goss P; Lee A; Neven P; Reid DM; Curto M; Vukicevic S;
    J Natl Cancer Inst; 2010 Nov; 102(22):1706-15. PubMed ID: 21051656
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Usefulness of technetium-99m tetrofosmin mammoscintigraphy as compared to mammography for detecting and differentiating palpable breast masses of young Taiwanese women.
    Hoi YJ; Hsieh JF; Tsai SC; Sun SS; Kao CH
    Anticancer Res; 2000; 20(3B):2061-4. PubMed ID: 10928152
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Biennial versus annual mammography and the risk of late-stage breast cancer.
    White E; Miglioretti DL; Yankaskas BC; Geller BM; Rosenberg RD; Kerlikowske K; Saba L; Vacek PM; Carney PA; Buist DS; Oestreicher N; Barlow W; Ballard-Barbash R; Taplin SH
    J Natl Cancer Inst; 2004 Dec; 96(24):1832-9. PubMed ID: 15601639
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Wolfe mammographic parenchymal patterns and breast cancer risk.
    Sickles EA
    AJR Am J Roentgenol; 2007 Feb; 188(2):301-3. PubMed ID: 17242234
    [No Abstract]   [Full Text] [Related]  

  • 46. Clinical and pathological factors predictive of lymph node status in women with screen-detected breast cancer.
    Gill PG; Luke CG; Roder DM
    Breast; 2006 Oct; 15(5):640-8. PubMed ID: 16517164
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mammography of breast carcinoma in women who have mutations of the breast cancer gene BRCA1: initial experience.
    Helvie MA; Roubidoux MA; Weber BL; Merajver SD
    AJR Am J Roentgenol; 1997 Jun; 168(6):1599-602. PubMed ID: 9168735
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Breast Cancer Risk in Sexual Minority Women during Routine Screening at an Urban LGBT Health Center.
    Clavelle K; King D; Bazzi AR; Fein-Zachary V; Potter J
    Womens Health Issues; 2015; 25(4):341-8. PubMed ID: 26060123
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Ultrasound detection of breast cancer with normal mammogram].
    Schlecht I; Hadijuana J; Hosten N; Oellinger H; Minguillon C; Bomhard T; Lichtenegger W; Felix R
    Aktuelle Radiol; 1995 Sep; 5(5):297-300. PubMed ID: 7495891
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The mammogram war.
    Begley S
    Newsweek; 1997 Feb; 129(8):54-8. PubMed ID: 10164990
    [No Abstract]   [Full Text] [Related]  

  • 51. The National Breast and Cervical Cancer Early Detection Program: report on the first 4 years of mammography provided to medically underserved women.
    May DS; Lee NC; Nadel MR; Henson RM; Miller DS
    AJR Am J Roentgenol; 1998 Jan; 170(1):97-104. PubMed ID: 9423608
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 99mTc-MIBI prone scintimammography in patients with high and intermediate risk mammography.
    Scopinaro F; Ierardi M; Porfiri LM; Tiberio NS; De Vincentis G; Mezi S; Cannas P; Gigliotti T; Marzetti L
    Anticancer Res; 1997; 17(3B):1635-8. PubMed ID: 9179209
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness: the next question for breast cancer screening.
    Harris R
    J Natl Cancer Inst; 2005 Jul; 97(14):1021-3. PubMed ID: 16030293
    [No Abstract]   [Full Text] [Related]  

  • 54. Technetium-99m sestamibi in the diagnosis of breast cancer. The Mayagüez Medical Center experience.
    Farías-Jimenez J; Rivera A; Carlo VM
    Bol Asoc Med P R; 2001; 93(1-12):9-11. PubMed ID: 12755069
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Breast density gains acceptance as breast cancer risk factor.
    Brower V
    J Natl Cancer Inst; 2010 Mar; 102(6):374-5. PubMed ID: 20215595
    [No Abstract]   [Full Text] [Related]  

  • 56. Breast cancer risk reduction: what do we know and where should we go?
    Prout MN
    Medscape Womens Health; 2000; 5(5):E4. PubMed ID: 11113777
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Strengths and limitations of breast cancer risk assessment.
    Baltzell K; Wrensch MR
    Oncol Nurs Forum; 2005 May; 32(3):605-16. PubMed ID: 15897935
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.
    Glass AG; Lacey JV; Carreon JD; Hoover RN
    J Natl Cancer Inst; 2007 Aug; 99(15):1152-61. PubMed ID: 17652280
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Absolute risk models for subtypes of breast cancer.
    Gail MH; Anderson WF; Garcia-Closas M; Sherman ME
    J Natl Cancer Inst; 2007 Nov; 99(22):1657-9. PubMed ID: 18000214
    [No Abstract]   [Full Text] [Related]  

  • 60. Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study.
    Partridge A; Adloff K; Blood E; Dees EC; Kaelin C; Golshan M; Ligibel J; de Moor JS; Weeks J; Emmons K; Winer E
    J Natl Cancer Inst; 2008 Feb; 100(4):243-51. PubMed ID: 18270338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.